Top-News
gemini genomics adr - hat jemand infos? o.T.
Beiträge:
3
Zugriffe: 700 / Heute: 1
Zugriffe: 700 / Heute: 1
|
Gemini Genomics Announces Key Scientific Appointments to Expand Drug Target Discovery Expertise
TUESDAY, DECEMBER 19, 2000 7:32 AM
- BusinessWire
CAMBRIDGE, U.K., Dec 19, 2000 (BW:GMNI), a world leader in clinical genomics, today announced that Steven Butcher, Ph.D. and Anders Berkenstam, Ph.D. have joined the company. Steven Butcher will join as Vice-President Science with responsibility for the scientific operations of the company. Anders Berkenstam will join as Director of Science at Gemini Genomics AB, the company's operations in Uppsala, Sweden. Dr. Butcher and Dr. Berkenstam, who both join from Pharmacia & Upjohn, have over 25 years combined experience in drug discovery.
"We are delighted that scientists as talented as Dr. Butcher and Dr. Berkenstam are joining Gemini," stated Dr. Patrick Kleyn, Chief Scientific Officer of Gemini Genomics. "Their scientific background, particularly in the area of drug target discovery and validation, coupled with their commercial experience make them an invaluable addition to the company. They will be leading the company's transition into drug discovery as it capitalizes on its recent disease gene and protein discoveries".
Dr. Butcher, most recently served as the Director of Target Discovery at Pharmacia & Upjohn in Stockholm Sweden, where he was promoted from his position as Head of Biochemistry & Cell Biology that he had held since 1997. From 1992-1997, he was supported by a prestigious Royal Society University Research Fellowship at the University of Edinburgh where he focused on the discovery of new drugs for the treatment of stroke and Alzheimers disease. During his tenure at the University, he was instrumental in establishing the Fujisawa Institute of Neuroscience, one of the first collaborations between a Japanese pharmaceutical company and a UK academia.
Dr. Berkenstam, is a world-renowned expert in intracellular receptors and joins Gemini from Pharmacia & Upjohn where he served as Program Coordinator for the Target Discovery activities. He was the originator of drug discovery projects focused on the application of intracellular receptor biology to the treatment of metabolic diseases, including Type 2 Diabetes. He has made seminal discoveries in the field of intracellular receptors and has patented novel genes involved in drug metabolism. Prior to joining Pharmacia, he was an Associate Professor of Experimental Endocrinology at the Karolinska Institute and was a scientific advisor for the biotechnology company KaroBioAB. He gained his Ph.D. in molecular biology from the Karolinska Institute.
Gemini is a clinical genomics company focused on the discovery and commercialization of novel gene-based targets. Gemini's approach integrates comprehensive clinical data and detailed genetic information from a wide range of human population groups, including twins, disease affected families, isolated (founder) populations and drug trial subjects. By investing in leading edge bioinformatics technologies, Gemini is able to effectively apply these resources to the acceleration of disease gene identification, target discovery, and drug development. With offices in the United States, United Kingdom, and Sweden, Gemini aims to maximize revenue generation arising from the commercialization of its discoveries by retaining control over the gene discovery process and taking advantage of the greater potential value offered by later-stage licensing opportunities. For more information about Gemini Genomics, visit the company's website, www.gemini-genomics.com.
Statements in this press announcement regarding Gemini's business, which are not historical facts, are "forward-looking statements" that involve risks and uncertainties. These risks and uncertainties include discovering and developing the potential applications based on this association and developing increased understanding of complex disorders.
CONTACT: Gemini Genomics plc
Paul Kelly, M.D., President and CEO
+44-1223-435300
or
Patrick Kleyn, P.h.D, Chief Scientific Officer
+1 617 527 4198
or
Tammy Bishop, Investor Relations
+1 617 527 4198
or
Thomson Financial/Carson
Europe - Mary Clark
+44 207 422 4061
North America - Peggy Sung
+1 212 510 9307
pvcharts.quicken.com/bin/...owVol=1&showsplits=1&amount=10000" style="max-width:560px" >Analyst Ratings Analysts
Today Analysts
1 month ago Analysts
2 months ago Analysts
3 months ago
1 - Strong Buy 2 2 1 1
2 - Buy 1 1 1 0
3 - Hold 0 0 0 0
4 - Sell 0 0 0 0
5 - Strong Sell 0 0 0 0
Consensus Rating
(strong buy) 1 - 5 (strong sell) 1.17 1.17 1.25 1.00
www.quicken.com/investments/estimates/?symbol=GMNI
gruß
proxi
TUESDAY, DECEMBER 19, 2000 7:32 AM
- BusinessWire
CAMBRIDGE, U.K., Dec 19, 2000 (BW:GMNI), a world leader in clinical genomics, today announced that Steven Butcher, Ph.D. and Anders Berkenstam, Ph.D. have joined the company. Steven Butcher will join as Vice-President Science with responsibility for the scientific operations of the company. Anders Berkenstam will join as Director of Science at Gemini Genomics AB, the company's operations in Uppsala, Sweden. Dr. Butcher and Dr. Berkenstam, who both join from Pharmacia & Upjohn, have over 25 years combined experience in drug discovery.
"We are delighted that scientists as talented as Dr. Butcher and Dr. Berkenstam are joining Gemini," stated Dr. Patrick Kleyn, Chief Scientific Officer of Gemini Genomics. "Their scientific background, particularly in the area of drug target discovery and validation, coupled with their commercial experience make them an invaluable addition to the company. They will be leading the company's transition into drug discovery as it capitalizes on its recent disease gene and protein discoveries".
Dr. Butcher, most recently served as the Director of Target Discovery at Pharmacia & Upjohn in Stockholm Sweden, where he was promoted from his position as Head of Biochemistry & Cell Biology that he had held since 1997. From 1992-1997, he was supported by a prestigious Royal Society University Research Fellowship at the University of Edinburgh where he focused on the discovery of new drugs for the treatment of stroke and Alzheimers disease. During his tenure at the University, he was instrumental in establishing the Fujisawa Institute of Neuroscience, one of the first collaborations between a Japanese pharmaceutical company and a UK academia.
Dr. Berkenstam, is a world-renowned expert in intracellular receptors and joins Gemini from Pharmacia & Upjohn where he served as Program Coordinator for the Target Discovery activities. He was the originator of drug discovery projects focused on the application of intracellular receptor biology to the treatment of metabolic diseases, including Type 2 Diabetes. He has made seminal discoveries in the field of intracellular receptors and has patented novel genes involved in drug metabolism. Prior to joining Pharmacia, he was an Associate Professor of Experimental Endocrinology at the Karolinska Institute and was a scientific advisor for the biotechnology company KaroBioAB. He gained his Ph.D. in molecular biology from the Karolinska Institute.
Gemini is a clinical genomics company focused on the discovery and commercialization of novel gene-based targets. Gemini's approach integrates comprehensive clinical data and detailed genetic information from a wide range of human population groups, including twins, disease affected families, isolated (founder) populations and drug trial subjects. By investing in leading edge bioinformatics technologies, Gemini is able to effectively apply these resources to the acceleration of disease gene identification, target discovery, and drug development. With offices in the United States, United Kingdom, and Sweden, Gemini aims to maximize revenue generation arising from the commercialization of its discoveries by retaining control over the gene discovery process and taking advantage of the greater potential value offered by later-stage licensing opportunities. For more information about Gemini Genomics, visit the company's website, www.gemini-genomics.com.
Statements in this press announcement regarding Gemini's business, which are not historical facts, are "forward-looking statements" that involve risks and uncertainties. These risks and uncertainties include discovering and developing the potential applications based on this association and developing increased understanding of complex disorders.
CONTACT: Gemini Genomics plc
Paul Kelly, M.D., President and CEO
+44-1223-435300
or
Patrick Kleyn, P.h.D, Chief Scientific Officer
+1 617 527 4198
or
Tammy Bishop, Investor Relations
+1 617 527 4198
or
Thomson Financial/Carson
Europe - Mary Clark
+44 207 422 4061
North America - Peggy Sung
+1 212 510 9307
Today Analysts
1 month ago Analysts
2 months ago Analysts
3 months ago
1 - Strong Buy 2 2 1 1
2 - Buy 1 1 1 0
3 - Hold 0 0 0 0
4 - Sell 0 0 0 0
5 - Strong Sell 0 0 0 0
Consensus Rating
(strong buy) 1 - 5 (strong sell) 1.17 1.17 1.25 1.00
www.quicken.com/investments/estimates/?symbol=GMNI
gruß
proxi
Es gibt keine neuen Beiträge.
Neueste Beiträge aus dem Technology All Share (Performance) Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
11 | 1.118 | USU Software --- Cashwert fast auf ATL -- | Lalapo | MrTrillion3 | 01.12.24 18:01 | |
| 11 | 523 | Elmos Semiconductor | Jorgos | Highländer49 | 08.11.24 18:23 | |
| 19 | Bitte an Ariva | Spitfire33 | taos | 28.09.24 11:26 | ||
| 68 | Comroad Kursziel 5 Euro in 3 Monaten! | BWLer | KevinRoberts | 19.09.24 12:03 | ||
| 14 | Hallo Agilent-Aktionäre | Anke Mankanke | cfgi | 21.08.24 22:29 |
